Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05241444 · ClinicalTrials.gov registry record · Phase 1
CD4^LVFOXP3 in Participants With IPEX
A Phase 1 study of IPEX, sponsored by Bacchetta, Rosa, MD.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT05241444 is a Phase 1 study of IPEX that is actively recruiting participants, run by Bacchetta, Rosa, MD. The registered enrollment target is 30 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05241444, a Phase 1 study of IPEX, is actively recruiting participants, sponsored by Bacchetta, Rosa, MD.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This first-in-human, Phase 1 clinical trial will test the feasibility of the manufacturing and the safety of the administration of CD4\^LVFOXP3 in up to 30 evaluable human participants with IPEX and evaluate the impact of the CD4\^LVFOXP3 infusion on the disease.
Conditions Studied
Interventions
- BIOLOGICAL CD4^LVFOXP3
Study Locations (1)
California
- Lucile Packard Children's Hospital - Palo Alto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2022-03-22 |
| Est. Completion | 2037-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05241444
The ClinicalTrials.gov registry entry for NCT05241444 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bacchetta, Rosa, MD, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with IPEX appearing as the primary indexed condition, and to 1 intervention - of which CD4^LVFOXP3 is the first listed.
NCT05241444 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT05241444 about?
NCT05241444 is a clinical study titled "CD4^LVFOXP3 in Participants With IPEX". This first-in-human, Phase 1 clinical trial will test the feasibility of the manufacturing and the safety of the administration of CD4\^LVFOXP3 in up to 30 evaluable human participants with IPEX and evaluate the impact of the CD4\^LVFOXP3 infusion on the disease.
What is the current status of trial NCT05241444?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2022-03-22. Estimated completion is 2037-02.
What conditions does trial NCT05241444 study?
This clinical trial studies the following conditions: IPEX.
What interventions are being tested in trial NCT05241444?
The interventions under investigation include: CD4^LVFOXP3 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05241444?
This trial is sponsored by Bacchetta, Rosa, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05241444 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.